A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis

NCT04633447 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

53

Enrollment

INDUSTRY

Sponsor class

Stopped The study primary endpoint was not met

Conditions

Giant Cell Arteritis

Interventions

DRUG: Guselkumab
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC